Inflammatory and cardiac biomarkers in pulmonary arterial hypertension: The prognostic role of IL-34

被引:1
|
作者
Bolayir, Hasan Ata [1 ]
Karasu, Mehdi [2 ]
Gelen, Mehmet Ali [2 ]
Akin, Yusuf [2 ]
Cecen, Erkan [3 ]
Kucuk, Ugur [4 ]
Bulu, Aykut [5 ]
机构
[1] Malatya Turgut Ozal Universitesi Kardiyoloji ABD, Dept Cardiol, Malatya, Turkiye
[2] Fethi Sekin Sehir Hastanesi, Dept Cardiol, Elazig, Turkiye
[3] Firat Universitesi Tip Fakultesi Hastanesi, Dept Cardiol, Elazig, Turkiye
[4] Canakkale 18 Mart Universitesi Kardiyoloji ABD, Dept Cardiol, Canakkale, Turkiye
[5] Fethi Sekin Sehir Hastanesi, Dept Internal Med, Elazig, Turkiye
来源
HEART & LUNG | 2025年 / 69卷
关键词
Pulmonary arterial hypertension (PAH); IL-34; Inflammation; Biomarkers; Right Ventricular Dysfunction; EXPRESSION; SURVIVAL; CYTOKINE; RECEPTOR;
D O I
10.1016/j.hrtlng.2024.10.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary artery pressure with significant morbidity and mortality. Inflammatory processes are crucial in PAH pathogenesis, with inflammatory cells and mediators present early in disease progression. IL-34 involvement in inflammatory pathways suggests that IL-34 could be an important player in the progression of PAH, influencing both pulmonary pressures and vascular changes. Objective: The purpose of this study was to investigate the correlation between IL-34 levels and pulmonary arterial hypertension (PAH), aiming to enhance the understanding of the molecular mechanisms underlying PAH and explore IL-34's potential as a biomarker. Methods: Consecutive PAH patients diagnosed via right-heart catheterization at Malatya Turgut Ozal E & gbreve;itim ve Ara & scedil;t & imath;rma Hastanesi (Dec 2022 - Apr 2024) were enrolled. Patients were classified into low-risk and high-risk groups based on comprehensive risk assessments that included clinical parameters, hemodynamic measurements and biomarkers, in-line with ESC/ERS guidelines. Serum IL-34, hs-CRP, and NT-proBNP levels were measured and compared with those of healthy controls. Echocardiographic assessments and statistical analyses, including ROC analysis, were conducted to evaluate biomarker significance and predictive capabilities. Results: The mean age of low-risk and high-risk PAH patients was 42 +/- 7.2 years and 45 +/- 5.5 years, respectively. The mean age of the control group was 40 +/- 6.4 years. Males comprised 54.29 % of the low-risk group, 56 % of the high-risk group, and 53.3 % of the control group. IL-34 and hs-CRP levels were significantly elevated in PAH patients compared to controls. IL-34 correlated positively with systolic pulmonary artery pressure, RA area, and NT-proBNP levels. Multivariate analysis revealed that IL-34 and hs-CRP were independent predictors of PAH. IL-34 levels>29.8 pg/mL predicted PAH with 78 % sensitivity and 69 % specificity, while levels >44.4 pg/mL predicted high-risk PAH with 84 % sensitivity and 77 % specificity. Conclusion: Elevated IL-34 and hs-CRP levels are associated with PAH severity and right ventricular dysfunction, suggesting IL-34's potential as a diagnostic and prognostic biomarker. Further research is needed to validate these findings and explore IL-34-targeted therapies in pH management.
引用
收藏
页码:202 / 207
页数:6
相关论文
共 50 条
  • [1] Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension
    Al-Naamani, Nadine
    Palevsky, Harold I.
    Lederer, David J.
    Horn, Evelyn M.
    Mathai, Stephen C.
    Roberts, Kari E.
    Tracy, Russell P.
    Hassoun, Paul M.
    Girgis, Reda E.
    Shimbo, Daichi
    Post, Wendy S.
    Kawut, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (01) : 25 - 30
  • [2] The Critical Role of IL-34 in Osteoclastogenesis
    Chen, Zhi
    Buki, Kalman
    Vaaraniemi, Jukka
    Gu, Guoliang
    Vaananen, H. Kalervo
    PLOS ONE, 2011, 6 (04):
  • [3] Targeting IL-34 in inflammatory autoimmune diseases
    Xu, Wang-Dong
    Huang, An-Fang
    Fu, Lu
    Liu, Xiao-Yan
    Su, Lin-Chong
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (12) : 21810 - 21816
  • [4] Cytokines as prognostic biomarkers in pulmonary arterial hypertension
    Boucly, Athenais
    Tu, Ly
    Guignabert, Christophe
    Rhodes, Christopher
    De Groote, Pascal
    Prevot, Gregoire
    Bergot, Emmanuel
    Bourdin, Arnaud
    Beurnier, Antoine
    Roche, Anne
    Jevnikar, Mitja
    Jais, Xavier
    Montani, David
    Wilkins, Martin R.
    Humbert, Marc
    Sitbon, Olivier
    Savale, Laurent
    EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (03)
  • [5] Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension
    Jardim, Carlos
    Souza, Rogerio
    CURRENT HYPERTENSION REPORTS, 2015, 17 (06)
  • [6] The role of inflammatory biomarkers in the arterial hypertension
    Rafaqat, Saira
    Rafaqat, Sana
    Ijaz, Hafsa
    ARTERIAL HYPERTENSION, 2023, 27 (01): : 13 - 23
  • [7] Role of IL-34 and its receptors in inflammatory diseases
    Shang, Jiameng
    Xu, Yuxin
    Pu, Shengdan
    Sun, Xiaotong
    Gao, Xinyuan
    CYTOKINE, 2023, 171
  • [8] An Expanding Role of Biomarkers in Pulmonary Arterial Hypertension
    Yildiz, Mustafa
    Sahin, Alparslan
    Behnes, Michael
    Akin, Ibrahim
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2017, 18 (06) : 491 - 494
  • [9] Prognostic Significance of Proteomics-Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension
    Yokokawa, Tetsuro
    Boucherat, Olivier
    Martineau, Sandra
    Lemay, Sarah-Eve
    Breuils-Bonnet, Sandra
    Krishna, Vinod
    Kalyana-Sundaram, Shanker
    Jeyaseelan, Jey
    Potus, Francois
    Bonnet, Sebastien
    Provencher, Steeve
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (12):
  • [10] Prognostic biomarkers in pediatric pulmonary arterial hypertension
    Ploegstra, Mark-Jan
    Berger, Rolf M. F.
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2021, 11 (04) : 1089 - 1101